Revolutionary Approach to Arrhythmia Detection
In the United States, more than 25 million people experience difficult-to-diagnose arrhythmia. These numbers are expected to increase due to the rising aging population.*
Cardiac Insight is focused on the future innovation of patient care by providing technology solutions that drive improved patient-physician collaboration, resulting in earlier diagnosis, treatment and improved cost savings.
Cardea SOLO™ is intended to enhance health care for the millions of patients who suffer from arrhythmia by providing quick, easy and informative heart rhythm data to the physician through an affordable and non-intrusive device.
The wearable sensor is indicated for use on adult patients who may be asymptomatic or who may suffer from transient symptoms such as palpitations, dizziness, anxiety, fatigue, syncope (fainting), pre-syncope, light-headedness, shortness of breath or who are at risk of developing atrial fibrillation, and where a software-assisted analysis of an ambulatory ECG could identify potential cardiac causes of these symptoms.
Cardea SOLO™ is lead-less, water-resistant and disposable—a lightweight device weighing less than an ounce (approximately 25 grams). The sensing device can be worn for up to seven days, recording with high accuracy every heartbeat for analysis while allowing patients to engage in their normal routine of daily activities, including exercise, sleep and showering.
Patients interact directly with their own doctor throughout the process, eliminating the need to navigate referrals to other clinicians as is likely with other diagnostic modalities.
Once applied in your office, there is no patient action for the duration of the wear. Your patient may record symptoms with a simple touch and note corresponding activity in their patient diary. At the conclusion of the wear period, patients return to your office where a full diagnostic report can be generated in minutes.
*Source: American Heart Association Heart Disease and Stroke Statistics 2005:1-61